on AMOEBA (EPA:ALMIB)
Amoéba Prepares for US Launch of AXPERA Product Line by 2025
Chassieu, France, August 28, 2024 - Amoéba, a greentech firm specializing in natural microbiological solutions, announced the US Environmental Protection Agency (EPA) has deemed its biocontrol products' registration dossier complete and admissible.
Amoéba aims to accelerate its industrial and commercial development following the US approval of its biocontrol active substance. The company successfully submitted a federal market authorization application for its biofungicide products AXPERA GREEN and AXPERA NOA in July 2024. The pre-approval process has begun, with a decision anticipated by mid-2025. This would cover the entire US, except California, which has a separate registration procedure.
Alongside the regulatory process, Amoéba collaborates with Dunham Trimmer to prepare for the commercial launch of AXPERA-based solutions. Should approval be granted within the projected timeline, distribution contracts could be signed by the end of 2025.
In Europe, the European Food Safety Authority's review of the active substance dossier is nearly complete, with a final report expected by December 2024.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all AMOEBA news